The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Ropeg in polycythemia vera: long-term PROUD-PV and CONTI-PV results
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the results from the long-term use of ropeginterferon alpha-2b (ropeg) in polycythemia vera (PV). Data shows ropeg minimizes the occurrence of thromboembolic events and is capable of inducing deep molecular responses, unlike hydroxyurea. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
